Agenus Schedules Conference Call to Discuss the Company’s Minority Cash Holdings at SVB
March 11 2023 - 11:24AM
Agenus (Nasdaq: AGEN), a clinical-stage company with a pipeline of
therapies designed to activate the body's immune system to fight
cancer and infections, today announced that it will hold a
conference call to provide detail and to answer any questions
regarding its minority cash holdings at Silicon Valley Bank (SVB)
at 8:30 a.m. ET on Monday, March 13th.
Conference CallDial-in numbers: (646) 307-1963
(US) or (800) 715-9871 (International)Conference ID: 9540056.
About AgenusAgenus is a clinical-stage
immuno-oncology company focused on the discovery and development of
therapies that engage the body's immune system to fight cancer and
infections. The Company's vision is to expand the patient
populations benefiting from cancer immunotherapy by pursuing
combination approaches that leverage a broad repertoire of antibody
therapeutics, adoptive cell therapies (through its subsidiary MiNK
Therapeutics), and adjuvants (through its subsidiary SaponiQx). The
Company is equipped with a suite of antibody discovery platforms
and a state-of-the-art GMP manufacturing facility with the capacity
to support clinical programs. Agenus is headquartered in Lexington,
MA. For more information, please visit www.agenusbio.com and
our Twitter handle @agenus_bio. Information that may be important
to investors will be routinely posted on our website and
Twitter.
ContactAgenus Inc.Zack ArmenHead of Investor
Relations917-362-1370zack.armen@agenusbio.com
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From May 2024 to Jun 2024
Agenus (NASDAQ:AGEN)
Historical Stock Chart
From Jun 2023 to Jun 2024